NICE NSCLC nod for Boehringer but not Lilly
This article was originally published in Scrip
Executive Summary
The UK health technology assessment body NICE has given the green light for Boehringer Ingelheim's targeted non-small cell lung cancer treatment Giotrif (afatinib) to be funded on the National Health Service.